Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor

Figure 3

Representative MRI slices of a 29-year-old male with D-TGCT in the hip 12 months after the initiation of pexidartinib. Post-pexidartinib treatment coronal (a, b) and axial (c) MR imaging demonstrates persistent end stage hip arthritis () but significant reduction in TGCT tumor burden tracking along the anterior hip into the pelvis (arrowhead) as well as significant reduction of both the ischiofemoral and anterior psoas tumor burden (arrow).

(a)

(b)

(c)